Aspirin use, body mass index, physical activity, plasma C-peptide, and colon cancer risk in US health professionals

American Journal of Epidemiology

Volumn 174, Issue 4, 2011, Pages 459-467

  Zhang, Xuehong ^a,b   Smith Warner, Stephanie A ^a   Chan, Andrew T ^b,c   Wu, Kana ^a,b   Spiegelman, Donna ^a   Fuchs, Charles S ^b,d   Willett, Walter C ^a,b   Giovannucci, Edward L ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Additive model; aspirin; body mass index; C peptide; cohort studies; colonic neoplasms; motor activity; multiplicative model

Indexed keywords

ACETYLSALICYLIC ACID; C PEPTIDE;

ANTIBODY; BODY MASS; CANCER; COHORT ANALYSIS; HEALTH RISK; MULTIVARIATE ANALYSIS; PEPTIDE; PUBLIC HEALTH;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CANCER RISK; CASE CONTROL STUDY; CLINICAL EVALUATION; COLON CANCER; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH PRACTITIONER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OBESITY; PHYSICAL ACTIVITY; RISK FACTOR; UNITED STATES;

ADULT; AGED; ASPIRIN; BODY MASS INDEX; C-PEPTIDE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; FEMALE; HEALTH PERSONNEL; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOTOR ACTIVITY; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK; UNITED STATES;

UNITED STATES;

EID: 80051488557     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr115     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121(4):241-246.
3. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995; 333(10):609-614.
4. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914-923. (Pubitemid 41215460)
5. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134(1):21-28. (Pubitemid 350309311)
6. Dubé C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. U.S. Preventive Services Task Force. Ann Intern Med. 2007; 146(5):365-375. (Pubitemid 351650597)
7. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573): 1603-1613. (Pubitemid 46710123)
8. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5): 501-507.
9. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376(9754):1741-1750.
10. U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146(5): 361-364.
11. Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122(5):327-334.
12. Martínez ME, Giovannucci E, Spiegelman D, et al. Leisuretime physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst. 1997;89(13):948-955.
13. Martínez ME, Heddens D, Earnest DL, et al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst. 1999;91(11):950-953. (Pubitemid 29272521)
14. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006; 55(1):115-122. (Pubitemid 41820645)
15. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-2142. (Pubitemid 47010839)
16. Markowitz SD. Aspirin and colon cancer-targeting prevention? N Engl J Med. 2007;356(21):2195-2198.
17. Giovannucci E. Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence. J Womens Health (Larchmt). 2003;12(2):173-182. (Pubitemid 36546762)
18. Delage B, Rullier A, Capdepont M, et al. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers [electronic article]. Nutr J. 2007;6:20.
19. Fearon ER, Jones PA. Progressing toward a molecular description of colorectal cancer development. FASEB J. 1992; 6(10):2783-2790.
20. Kim S, Baron JA, Mott LA, et al. Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). Cancer Causes Control. 2006; 17(10):1299-1304. (Pubitemid 44772831)
21. Wei EK, Giovannucci E, Wu K, et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer. 2004; 108(3):433-442. (Pubitemid 37549610)
22. World Cancer Research Fund/American Institute for Cancer Research Expert Panel. Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington, DC: American Institute for Cancer Research; 2007.
23. Slattery ML, Samowitz W, Hoffman M, et al. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004;13(4):538-545. (Pubitemid 38737888)
24. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;86(suppl): 836S-842S.
25. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesityand diet-induced insulin resistance with salicylates or targeted disruption of Ikkb. Science. 2001;293(5535):1673-1677. (Pubitemid 32807849)
26. Bonser AM, Garcia-Webb P. C-peptide measurement: methods and clinical utility. Crit Rev Clin Lab Sci. 1984;19(4): 297-352.
27. Puckett CD. The Educational Annotation of ICD-9-CM; Diseases and Procedures Tabular Lists. Reno, NV: Channel Publishing, Ltd; 1986.
28. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119(5): 837-839. (Pubitemid 14142821)
29. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995; 87(17):1297-1302.
30. Meyer F, White E. Alcohol and nutrients in relation to colon cancer in middle-aged adults. Am J Epidemiol. 1993;138(4): 225-236. (Pubitemid 23263593)
31. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164(14):1519- 1524. (Pubitemid 38970471)
32. Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of selfreported waist and hip circumferences in men and women. Epidemiology. 1990;1(6):466-473.
33. Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol. 1994;23(5):991-999. (Pubitemid 24331214)
34. Chasan-Taber S, Rimm EB, Stampfer MJ, et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology. 1996;7(1): 81-86. (Pubitemid 26003850)
35. Meyer KA, Conigrave KM, Chu NF, et al. Alcohol consumption patterns and HbA1c, C-peptide and insulin concentrations in men. J Am Coll Nutr. 2003;22(3):185-194. (Pubitemid 36706265)
36. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B). 1972;34(2):187-220.
37. SAS Institute, Inc. SAS/STAT software: the PHREG prodedure: preliminary documentation. Cary, NC: SAS Institute, Inc; 1991.
38. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101-129.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
40. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.
41. Rothman KJ. Modern Epidemiology. Boston, MA: Little Brown and Company; 1986.
42. Karlson EW, Chang SC, Cui J, et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):54-60.
43. Lundberg M, Fredlund P, Hallqvist J, et al. A SAS program calculating three measures of interaction with confidence intervals. Epidemiology. 1996;7(6):655-656.
44. Andersson T, Alfredsson L, Källberg H, et al. Calculating measures of biological interaction. Eur J Epidemiol. 2005; 20(7):575-579. (Pubitemid 41126030)
45. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology. 1992;3(5):452-456.
46. Tjønneland A, Christensen J, Olsen A, et al. Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 2007;18(4):361-373. (Pubitemid 46434794)
47. Allison M, Garland C, Chlebowski R, et al. The association between aspirin use and the incidence of colorectal cancer in women. Women's Health Initiative Investigators. Am J Epidemiol. 2006;164(6):567-575. (Pubitemid 44412785)
48. Friis S, Poulsen AH, Sørensen HT, et al. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009; 20(5):731-740.
49. Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608-615. (Pubitemid 47073542)
50. Calton BA, Lacey JV Jr, Schatzkin A, et al. Physical activity and the risk of colon cancer among women: a prospective cohort study (United States). Int J Cancer. 2006;119(2): 385-391.
51. Slattery ML, Potter JD. Physical activity and colon cancer: confounding or interaction? Med Sci Sports Exerc. 2002; 34(6):913-919. (Pubitemid 34602792)
52. Abrahamson PE, King IB, Ulrich CM, et al. No effect of exercise on colon mucosal prostaglandin concentrations: a 12-month randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2351-2356. (Pubitemid 351196367)
53. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenaseindependent actions of cyclooxygenase inhibitors. FASEB J. 2001;15(12):2057-2072.
54. Giovannucci EL, Liu Y, Leitzmann MF, et al. A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med. 2005;165(9):1005-1010. (Pubitemid 40638120)
55. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96(7):546-553. (Pubitemid 38559579)